

Index

Note: Page numbers of article titles are in boldface type.

- Acebutolol, in hypertension, 612, 614
- Acetylsalicylic acid, monitoring of, 687, 689-692
- Acid-base disorders, in total parenteral nutrition, 710-711
- Acidosis, metabolic, in total parenteral nutrition, 710
- Agar dilution tests, in antimicrobial susceptibility testing, 500-504
- Alkalosis, metabolic, in total parenteral nutrition, 710-711
- Alkylating agents, monitoring of, 629
- Alpha-adrenergic blocking agents, in hypertension, 608-611
- Alpha-methyldopa, in hypertension, 610
- Amiloride, in hypertension, 619
- Amino acids, in total parenteral nutrition, 701-702
- Aminoglycosides, antimicrobial action of, 514
- chemistry of, 513-514
 - clinical use of, 515
 - dosage of, 524-526
 - microbial resistance to, 514-515
 - monitoring of, 513-529
 - dosing schedule and, 520-521
 - patient selection in, 519
 - quantitative methods for, 521-524
 - sample timing in, 519-520
 - pharmacokinetics of, 517-518
 - spectra of, 515
 - synergistic activity of, 507-508
 - toxicity of, 515-517
- Amiodarone, monitoring of, 568-569
- Anabolic steroids, in sports, 655-657
- monitoring of, 655-668
 - methods for, 657
 - with GC-MS, characteristics of, 658-660
 - confirmatory tests in, 657-658
 - for individual compounds, 666-667
 - for screening, 657-658
 - with combined fractions, 661-665
 - with nonconjugated compounds, 665-666
- Androgens, monitoring of, 655-668
- Angiotensin-converting enzyme inhibitors, in hypertension, 611-612
- Antagonism, of antimicrobials, 507
- Antianginal agents, monitoring of, 567-585
- Antiarrhythmics, classification of, 567-568
- monitoring of, 567-585
- Antibiotics. See also *Antimicrobials*.
- neoplastic, monitoring of, 630
- Antidepressants, cyclic. See *Cyclic antidepressants*.
- Antihypertensive agents, classification of, 609
- monitoring of, 607-623
- Anti-inflammatory drugs, monitoring of, 687-697
- types of, 687
- Antimetabolites, monitoring of, 629
- Antimicrobials, antagonistic activity of, 507
- distribution of, theoretical vs. actual, 504
 - susceptibility testing for, in combination use, 507-509
 - in drug monitoring, 499-511
 - minimal bactericidal concentrations in, 505-506
 - quantitative methods for, 500-504
 - routine use of, 504-505
 - serum bactericidal titers in, 506
- Antineoplastic drugs, classes of, 627-630
- monitoring of, 625-639
 - criteria for, 636-637
 - in oncologic practice, 632-635
 - in oncologic research, 635-636
 - methods for, 630-632
 - pharmacokinetics of, 627
 - properties of, 625-627
- Aspirin, monitoring of, 687, 689-692
- Atenolol, in hypertension, 612, 614
- Autobac system, in antimicrobial susceptibility testing, 503-504
- Bacteria, antimicrobial susceptibility of. See under *Antimicrobials*.

- Beta-adrenoreceptor receptor blocking agents, in hypertension, 612-613
- Beta-lactams, synergistic activity of, 507-508
- Biologic assay, in aminoglycoside monitoring, 521
- in antineoplastic drug monitoring, 631
- Broth dilution tests, in antimicrobial susceptibility testing, 500-504
- Calan. See *Verapamil*.
- Calcium channel blocking agents
- in hypertension, 613, 615-618
- monitoring of, 574-578
- Cancer, antimicrobial susceptibility testing in, 506
- drugs for. See *Antineoplastic drugs*.
- Cannabinoids, chemistry of, 641-642
- monitoring of, 641-653
- methods for, 644-648
- pharmacokinetics of, 642-644
- therapeutic use of, 649
- Captopril, in hypertension, 611
- Carbohydrates, in total parenteral nutrition, 702-704
- Carbon dioxide, excess production of, in total parenteral nutrition, 703
- Cardiac agents. See also *Digitalis glycosides*. monitoring of, 567-585
- Cardizem. See *Diltiazem*.
- Catheter, complications from, in total parenteral nutrition, 706-708
- CELIA (competitive enzyme-linked immunoassay), in chloramphenicol monitoring, 533-534
- Cesamet. See *Δ-Tetrahydrocannabinol*.
- Checkerboard titration, in antimicrobial susceptibility testing, 502
- Chemotherapy drugs. See *Antineoplastic drugs*.
- Chloramphenicol, monitoring of, 531-534
- Chromatography, in aminoglycoside monitoring, 521-522
- in antineoplastic drug monitoring, 631
- in cannabinoid monitoring, 646, 648
- in chloramphenicol monitoring, 533
- in cyclosporine monitoring, 676-677
- in diltiazem monitoring, 578
- in flecainide monitoring, 570-571
- in flucytosine monitoring, 542
- in methotrexate monitoring, 634-635
- in mexiletine monitoring, 572
- in nifedipine monitoring, 577
- in salicylate monitoring, 692
- in tocainide monitoring, 574
- in vancomycin monitoring, 537
- in verapamil monitoring, 576
- Clonidine, in hypertension, 610
- Colorimetric assay, in salicylate monitoring, 691-692
- Competitive enzyme-linked immunoassay (CELIA), in chloramphenicol monitoring, 533-534
- Congestive heart failure, digitalis glycosides in, 598
- Cordarone. See *Amiodarone*.
- Creatinine assay, in flucytosine monitoring, 542
- Cyclic antidepressants, classification of, 551-553
- monitoring of, 551-566
- concentration vs. response in, 559-561
- concentration vs. toxicity in, 561-562
- justification for, 553-554
- methods for, 558
- pharmacokinetics of, 554-556
- pitfalls in, 562-563
- sample collection in, 556-558
- Cyclosporine, 669-686
- administration of, 671-672
- drug interactions with, 681-683
- mechanism of action of, 670-671
- monitoring of, 674-679
- additional testing with, 675
- lipoprotein effects on, 678
- sample collection frequency in, 675
- sample type for, 677-678
- with liquid chromatography, 676-677
- with radioimmunoassay, 675-676
- origin of, 669-670
- pharmacokinetics of, 672-674
- structure of, 670
- therapeutic range of, 678
- toxicity of, 679-681
- uses of, 669
- Cytotoxic drugs. See *Antineoplastic drugs*.
- Delta-tetrahydrocannabinol. See *Δ-Tetrahydrocannabinol*.
- Depression, drugs for. See *Antidepressants*.
- Dextrose, in total parenteral nutrition, 702-704
- Diabetes mellitus, total parenteral nutrition and, 703-704
- Dialysis, aminoglycoside elimination by, 518
- total parenteral nutrition and, 704
- Dianabol, monitoring of, 666-667
- Diflunisal, monitoring of, 692
- Digitalis glycosides, chemistry of, 587-588
- in congestive heart failure, 598
- mechanism of action of, 588-589
- monitoring of, 587-606
- criteria for, 598-600
- postmortem, 601
- result interpretation in, 600-601
- pharmacokinetics of, 589-593
- toxicity of, treatment for, 601-602

- Digoxin, immunoassay for, 593-596
- Digoxin-like substances, endogenous, interference of, in digoxin monitoring, 597-598
- Diltiazem, in hypertension, 615-616
monitoring of, 577-578
- Dilution methods, in antimicrobial susceptibility testing, 501-502
- Diuretics, in hypertension, 618-619
- Drug monitoring, antimicrobial susceptibility tests in, 499-511
for aminoglycosides, 513-529
for androgenic anabolic steroids, 655-668
for antiangiinal agents, 567-585
for antiarrhythmics, 567-585
for antihypertensive agents, 607-623
for anti-inflammatory agents, 687-697
for antineoplastics, 625-639
for cannabinoids, 641-653
for cardiac drugs, 567-585
for cardiac glycosides, 587-606
for chloramphenicol, 531-534
for cyclic antidepressants, 551-566
for flucytosine, 541-543
for lithium, 545-550
for vancomycin, 534-538
- Ear, aminoglycoside effects on, 516
- Ektachem assay, in flucytosine monitoring, 542
- EMIT method, in cannabinoid monitoring, 645
in chloramphenicol monitoring, 533
- Enalapril, in hypertension, 611-612
- Endocarditis, antimicrobial susceptibility testing in, 505-506
- Enzyme assay, in chloramphenicol monitoring, 533
- Enzyme immunoassay, in aminoglycoside monitoring, 522-523
in cannabinoid monitoring, 645
in methotrexate monitoring, 634-635
- Ethacrynic acid, in hypertension, 619
- Fats. *See Lipids.*
- Flecainide, monitoring of, 569-571
- Flucytosine, monitoring of, 541-543
- Fluid overload, in total parenteral nutrition, 711
- Fluorescence immunoassay, in vancomycin monitoring, 537
- Fluorescence polarization immunoassay, in aminoglycoside monitoring, 523
in vancomycin monitoring, 537
- 5-Fluorocytosine, monitoring of, 541-543
- Fluorometric assay, in flecainide monitoring, 570
in flucytosine monitoring, 542
in nifedipine monitoring, 577
in salicylate monitoring, 692
in verapamil monitoring, 576
- Furosemide, in hypertension, 619
- Gas chromatography/mass spectrometry (GC-MS), in cannabinoid monitoring, 648
in steroid monitoring. *See under Anabolic steroids.*
- Glucose, in total parenteral nutrition, 702-704
- Glycosides, cardiac. *See Digitalis glycosides.*
- Guanabenz, in hypertension, 610
- Hearing, aminoglycoside effects on, 516
- Hemodialysis, aminoglycoside elimination by, 518
- Heparin, in total parenteral nutrition, 707-708
- Hormones, anabolic steroidal. *See Anabolic steroids.*
neoplastic, monitoring of, 630
- Hydralazine, in hypertension, 620
- Hyperalimentation. *See Total parenteral nutrition.*
- Hypertension, pharmacotherapy in, 607-623
- Hypophosphatemia, in total parenteral nutrition, 708-709
- Ibuprofen, monitoring of, 692-693
- Immunoassay. *See also Radioimmunoassay.*
in aminoglycoside monitoring, 522-523
in antineoplastic drug monitoring, 631
in cannabinoid monitoring, 644-645
in chloramphenicol monitoring, 533-534
in digoxin monitoring, 593-596
in methotrexate monitoring, 634-635
in vancomycin monitoring, 537
- Immunosuppressants. *See Cyclosporine.*
- Indomethacin, monitoring of, 694
- Infection, antimicrobial susceptibility testing in. *See under Antimicrobials.*
catheter-related, in total parenteral nutrition, 706-707
- Inoculum preparation, in antimicrobial susceptibility testing, 500-501
- Insulin, in total parenteral nutrition, 704
- Interferon, monitoring of, 630

- Kidney, effects of aminoglycoside on, 516
 effects of cardiac glycosides on, 589
 effects of cyclosporine on, 679-680
- Kodak Ektachem assay, in flucytosine monitoring, 542
- Labetalol, in hypertension, 613, 614
- Latex bead agglutination, in aminoglycoside monitoring, 523
- Lipids, cross-reactivity of, in digoxin immunoassay, 595-596
 in total parenteral nutrition, 704-706
- Lipoprotein, affecting cyclosporine monitoring, 678
- Lithium, dosage of, 549
 formulations of, 547
 monitoring of, 545-550
 pharmacokinetics of, 547-548
 pharmacology of, 545-547
- Loop diuretics, in hypertension, 619
- Macrodilution method, in antimicrobial susceptibility testing, 501-502
- Marijuana, monitoring of, 641-653
- Marinol. See *Δ -Tetrahydrocannabinol*.
- MBC (minimal bactericidal concentration), in antimicrobial susceptibility testing, 501, 505-506
- Meningitis, antimicrobial susceptibility testing in, 505
- Metabolic acidosis, in total parenteral nutrition, 710
- Metabolic alkalosis, in total parenteral nutrition, 710-711
- Metabolic disorders, iatrogenic, in total parenteral nutrition, 708-711
- Methandienone, monitoring of, 666-667
- Methenolone, monitoring of, 667
- Methotrexate, monitoring of, 632-635
 high-dose, 632-633
 methods for, 634-635
 vs. therapeutic effectiveness, 634
 vs. toxicity, 633-634
- Methyldopa, in hypertension, 610
- Metoprolol, in hypertension, 612, 614
- Mexiletine, monitoring of, 571-572
- MIC (minimal bacteriostatic concentration), in antimicrobial susceptibility testing, 501-502, 504-505
- Microbiologic assay, in flucytosine monitoring, 542
- Microdilution method, in antimicrobial susceptibility testing, 501, 503
- Minimal bactericidal concentration (MBC), in antimicrobial susceptibility testing, 501, 505-506
- Minimal bacteriostatic concentration (MIC), in antimicrobial susceptibility testing, 501-502, 504-505
- Minoxidil, in hypertension, 620
- Monitoring, drug. See *Drug monitoring*, in total parenteral nutrition, 699-714
- Nabilone. See *Δ -Tetrahydrocannabinol*.
- Nadolol, in hypertension, 614
- Nandrolone, monitoring of, 663-664, 666
- Naproxen, monitoring of, 693
- Natelson's method, in salicylate monitoring, 691-692
- Natriuretic hormone, interference of, in digoxin monitoring, 597
- Nephrotoxicity, of aminoglycosides, 516
 of cyclosporine, 679-680
- Neutropenia, antimicrobial susceptibility testing in, 505
- Nifedipine, in hypertension, 615-616
 monitoring of, 576-577
- Nitrendipine, in hypertension, 616-617
- Nitrogen balance, estimation of, 700-701
- Nonsteroidal anti-inflammatory drugs (NSAIDs). See *Anti-inflammatory drugs*.
- 19-Nortestosterone. See *Nandrolone*.
- Nutrition, total parenteral. See *Total parenteral nutrition*.
- Olympic Games, anabolic steroid use in, 655-657
- Oncology, chemotherapy in. See *Antineoplastic drugs*.
- Ototoxicity, of aminoglycosides, 516
- Parenteral nutrition, total. See *Total parenteral nutrition*.
- Penicillin, synergistic activity of, 507-508
- Pharmacokinetics. See specific drug.
- Phenylbutazone, monitoring of, 693-694
- Phosphorus depletion, in total parenteral nutrition, 708-709
- Pindolol, in hypertension, 612, 614
- Piroxicam, monitoring of, 694
- Plant alkaloids, monitoring of, 629-630
- Potassium-sparing diuretics, in hypertension, 619
- Prazosin, in hypertension, 610-611
- Procardia. See *Nifedipine*.
- Propranolol, in hypertension, 614
- Protein, in total parenteral nutrition, 701-702

- Radial partition immunoassay, in aminoglycoside monitoring, 523
- Radioenzymatic assay, in aminoglycoside monitoring, 521-522
- Radioimmunoassay, in aminoglycoside monitoring, 522
- in cannabinoid monitoring, 645-646
- in cyclosporine monitoring, 675-676
- in vancomycin monitoring, 537
- Radioisotope labeling, in antineoplastic drug monitoring, 631-632
- Salicylates, monitoring of, 687, 689-692
- Sample collection, in cyclic antidepressant monitoring, 556-558
- Sandimmune. *see Cyclosporine.*
- SBT (serum bactericidal titer), in antimicrobial susceptibility testing, 502-503, 506
- Sepsis, catheter-related, in total parenteral nutrition, 706-707
- Serum bactericidal titer (SBT), in antimicrobial susceptibility testing, 502-503, 506
- Sotalol, in hypertension, 614
- Spirolactone, in hypertension, 619
- Sports, anabolic steroid use in, 655-657
- Stanozolol, monitoring of, 665-666, 667
- Steroids, anabolic. *See Anabolic steroids.*
- Streptomycin, synergistic activity of, 508
- Synergism, bactericidal, antimicrobial susceptibility testing and, 507-509
- Tambocor. *See Flecainide.*
- Testosterone-to-epitestosterone ratio, estimation of, 664-665
- Δ -Tetrahydrocannabinol (Δ -THC), chemistry of, 641-642
- pharmacokinetics of, 642-644
- therapeutic use of, 649
- Thiazide diuretics, in hypertension, 618-619
- Thrombosis, catheter-related, in total parenteral nutrition, 707-708
- Time-kill curve, in antimicrobial susceptibility testing, 502
- Timolol, in hypertension, 614
- Tocainide, monitoring of, 572-574
- Tonocard. *See Tocainide.*
- Total parenteral nutrition, carbohydrates in, 702-704
- catheter-related complications in, 706-708
- iatrogenic metabolic disorders in, 708-711
- lipids in, 704-706
- monitoring in, 699-714
- overfeeding in, 703
- patient assessment in, 700-701
- protein in, 701-702
- vs. prognosis, 701
- Transplantation, drugs for. *See Cyclosporine.*
- Triamterene, in hypertension, 619
- Trinder's method, in salicylate monitoring, 691-692
- Urine, androgenic anabolic steroids in, 655-668
- Vancomycin, monitoring of, 534-538
- Vasodilators, in hypertension, 619-620
- Verapamil, in hypertension, 617-618
- monitoring of, 574-576
- Vestibular function, aminoglycoside effects on, 516
- Warfarin, in total parenteral nutrition, 708

